TL;DR
This study identifies Muscleblind-like 3 (MBNL3) as a key driver of gastric adenocarcinoma (GAC) progression. They found that MBNL3, often overexpressed in GAC, promotes tumor growth, invasion, and blood vessel formation by activating the AKT/VEGFA pathway. Crucially, they demonstrate that MBNL3 is regulated by miR-302e, suggesting a novel therapeutic target for GAC.
What Problem Does This Paper Address?
Gastric adenocarcinoma (GAC) remains a significant cause of cancer-related deaths worldwide, despite advancements in treatment. Understanding the molecular mechanisms driving GAC progression is crucial for developing more effective therapies. While the Muscleblind-like 3 (MBNL3) protein has been implicated in other cancers, its specific role and regulatory pathways in GAC were largely unknown. This paper aims to elucidate the function of MBNL3 in GAC development and identify potential therapeutic targets.
Methods
The researchers employed a multi-pronged approach to investigate MBNL3's role in GAC:
- Expression Analysis: They analyzed MBNL3 mRNA and protein levels in GAC tissues and cell lines compared to normal controls using publicly available databases (GEPIA) and Western blotting.
- Functional Assays (In Vitro):
- Cell Proliferation: CCK-8 and EdU assays were used to assess how MBNL3 overexpression or knockdown affected the rate of cancer cell division.
- Cell Invasion: Transwell assays were performed to measure the ability of GAC cells to migrate through a barrier, indicating invasive potential.
- Angiogenesis: Tube formation assays using HUVECs (human umbilical vein endothelial cells) were conducted to evaluate MBNL3's impact on the formation of new blood vessels, a process vital for tumor growth.
- Molecular Mechanism Studies:
- miRNA Target Prediction and Validation: Bioinformatic tools (TargetScan, starbase, miRDB, tarbase) were used to predict miRNAs that might target MBNL3. Luciferase reporter assays were then employed to experimentally confirm the direct binding of miR-302e to MBNL3.
- Pathway Analysis: Western blotting was used to examine the activation status of key components of the PI3K/AKT/VEGFA signaling pathway (p-PI3K, PI3K, p-AKT, AKT, VEGFA) under different MBNL3 expression conditions and in response to pathway modulators (AKT activator 740 Y-P and inhibitor LY294002).
- Functional Assays (In Vivo): A mouse subcutaneous tumor model was established by injecting AGS cells with suppressed MBNL3 expression to assess the impact on tumor growth, volume, and weight. Immunohistochemistry (IHC) for Ki67, a marker of cell proliferation, was also performed.
Datasets
- Human GAC Tissues: Three paired GAC tissues and adjacent normal tissues were collected from Chaohu Hospital of Anhui Medical University.
- Public Databases: GEPIA (Gene Expression Profiling Interactive Analysis) and KM-plotter were used for analyzing MBNL3 mRNA expression and patient prognosis.
- Cell Lines: Normal human gastric epithelial cell line GES-1 and GAC cell lines AGS and MKN45 were used.
Key Insights and Ideas
- MBNL3 as a GAC Oncogene: The study provides strong evidence that MBNL3 is not just present but actively promotes GAC progression, correlating with poorer patient outcomes.
- The miR-302e/MBNL3 Axis: The discovery of miR-302e as a direct regulator of MBNL3 is a critical finding. This suggests a feedback loop or a regulatory mechanism where a tumor-suppressive miRNA (miR-302e) is counteracted by an oncogenic protein (MBNL3).
- AKT/VEGFA Pathway as a Key Mediator: The research clearly links MBNL3's pro-tumorigenic effects to the activation of the AKT/VEGFA pathway, a well-established pathway in cancer development. This provides a concrete molecular mechanism for MBNL3's actions.
- Therapeutic Potential: The identification of MBNL3 as a targetable molecule, regulated by miR-302e and acting through the AKT/VEGFA pathway, opens avenues for developing novel GAC therapies.
Key Results
- Elevated MBNL3 in GAC: MBNL3 mRNA and protein levels were significantly higher in GAC tissues and cell lines compared to normal counterparts. Patients with high MBNL3 expression showed a worse prognosis.
- MBNL3 Promotes GAC Hallmarks: Overexpression of MBNL3 enhanced GAC cell proliferation, invasion, and angiogenesis in vitro. Conversely, knockdown of MBNL3 suppressed these processes.
- miR-302e Targets MBNL3: miR-302e was confirmed to directly bind to and downregulate MBNL3 expression. Overexpression of miR-302e reduced MBNL3 levels, while its suppression led to increased MBNL3.
- miR-302e/MBNL3 Axis Modulates GAC: Rescue experiments showed that restoring MBNL3 expression could reverse the suppressive effects of miR-302e mimic on proliferation, invasion, and angiogenesis.
- MBNL3 Activates AKT/VEGFA: MBNL3 modulated the phosphorylation of PI3K and AKT, as well as VEGFA expression. Inhibition of MBNL3 reduced these levels, which could be rescued by an AKT activator (740 Y-P). Conversely, MBNL3 overexpression increased these levels, which were attenuated by an AKT inhibitor (LY294002).
- MBNL3 Promotes Tumor Growth In Vivo: Suppression of MBNL3 in AGS cells significantly reduced tumor size, volume, and weight in a mouse model, and decreased Ki67 expression.
Limitations and Future Work
- Phenotypic Scope: The authors acknowledge that their study focused on specific phenotypes (proliferation, invasion, angiogenesis) and suggest that future work should explore other aspects of GAC progression, such as autophagy, exosome secretion, and immune response.
- In Vivo Model Specificity: While the in vivo study demonstrated MBNL3's role in tumor growth, further investigations with more complex models could provide deeper insights.
- Therapeutic Translation: While MBNL3 is proposed as a bio-target, further research is needed to develop and test specific therapeutic strategies targeting this molecule or its regulatory axis.
Summary updated